{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.7","upperLimit":"97.0","value":"86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"Objective response rate (ORR) per investigator was defined as the percentage of subjects with CR or PR through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Part D, the response was assessed using the Lugano Classification Revised Staging System for nodal non-Hodgkin and cHL (Lugano criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC).","dispersionType":"95% Confidence Interval","groups":[{"description":"BV in combination with nivolumab as frontline therapy in adults aged 60 and above with cHL. BV (1.8 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle. Nivolumab (3 mg/kg) was administered as an IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Part D"}],"paramType":"NUMBER","populationDescription":"All subjects who received at least one dose of study drug","reportingStatus":"POSTED","timeFrame":"Up to 60 months","title":"ORR According to the Lugano Classification Revised Staging System for Nodal Non-Hodgkin and Hodgkin Lymphomas (Lugano Criteria) and the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) (Part D)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}